Active, not recruitingPhase 3NCT05130450
A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS)
Studying Familial lipoprotein lipase deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ionis Pharmaceuticals, Inc.
- Intervention
- Olezarsen(drug)
- Enrollment
- 60 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2028
Study locations (27)
- Diabetes/Lipid Management & Research Center, Huntington Beach, California, United States
- Excel Medical Clinical Trials, LLC, Boca Raton, Florida, United States
- Department of Pharmacy, Park Ridge, Illinois, United States
- University of Kansas Medical Center (KUMC), Kansas City, Kansas, United States
- CTSI Investigational Pharmacy, New York, New York, United States
- Milstein Hospital, New York, New York, United States
- IDS Central, Philadelphia, Pennsylvania, United States
- Ecogene-21, Chicoutimi, Quebec, Canada
- Institute de Recherches Cliniques de Montreal, Montreal, Quebec, Canada
- Nathalie Saint-Pierre, Montreal, Quebec, Canada
- Clinique des Maladies Lipidiques de Quebec Inc., Québec, Quebec, Canada
- Groupement Hospitalier Est- Pharmacie Secteur Essais Clinique, Bron, France
- Hôpital Bicêtre, Le Kremlin-Bicêtre, France
- Pharmacie Hopital de la Conception, Marseille, France
- Via Sergio Pansini 5, Naples, Italy
- +12 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05130450 on ClinicalTrials.govOther trials for Familial lipoprotein lipase deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGEARLY PHASE1NCT07371767CS-121 APOC3 Base Editing in Children and Adolescents With HyperchylomicronemiaShanghai Jiao Tong University School of Medicine
- RECRUITINGEARLY PHASE1NCT07176923CS-121 APOC3 Base Editing in FCSCorrectSequence Therapeutics Co., Ltd
- ACTIVE NOT RECRUITINGPHASE3NCT05185843A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With VolanesorsenIonis Pharmaceuticals, Inc.
- RECRUITINGNANCT04227678Postprandial Fatty Acid Metabolism in Subjects With Lipoprotein Lipase DeficiencyUniversité de Sherbrooke